Showing 2759 results
-
Event /Novartis announces the company’s financial results for the third quarter of 2025.
-
Story /Novartis-Harvard team identifies a new type of cell that is key to the disease.
-
Story /In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the…
-
Press release /Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy…
-
Event /Novartis announced the company’s financial results for the third quarter of 2024.
-
Event /Novartis announces the company’s financial results for the second quarter and first half of 2025.
-
Event /Novartis announces the company’s financial results for the first quarter of 2025.
-
Press release /Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo…
-
Press release /Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection…